The European Union's medications controller couldn't affirm from accessible information if women and young adults were at a higher danger of uncommon blood clots with low platelets after vaccination with AstraZeneca's COVID-19 jab.

European Medicines Agency (EMA) could not point out a specific risk factor that increased the chances of thrombosis with thrombocytopenia syndrome (TTS) from the shortcomings of the data collected.

The EU requested EMA to provide expert opinion after reports of TTS associatiated with the Vaxzevria vaccine earlier in the year after EU suspended the application of the jab.

EMA said there was no evidence that delaying the second dose influences risk of TSS.

“There is no evidence that delaying the second dose has any influence on the risk of TTS,” said EMA.

Read More

  1. How South Africa is playing a key role in AstraZeneca global clinical trial triumphs
  2. AstraZeneca, Tricog Health, Kenya Cardiac Society unite to combat heart failure with AI
  3. World Lung Cancer Day: AstraZeneca pioneers new era of care in Africa

Ema also did not give any definitive recommendations or advised on another vaccine for a second dose after a first jab Astraeneca